NCT06616389View on ClinicalTrials.gov

Study of ODX (OsteoDex) in Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

ODX (Osteodex)

Multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX.

Trial Locations (2)

14186

RECRUITING

Karolinska Universitetssjukhuset Huddinge Cancerstudieenheten M62, Stockholm

45180

RECRUITING

Uddevalla Sjukhus, Hematologens dagvård, Uddevalla

Sponsors

Lead Sponsor

DexTech Medical AB
All Listed Sponsors
lead

DexTech Medical AB

INDUSTRY